Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Bioventus Inc.BVS · Entity 4996 | Director · Fmr. CEO and Director | March 14, 2022 | April 21, 2023 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Bioventus Inc.
Report date March 14, 2022 · Filed April 21, 2023 · Amendment
Amendment: balances below belong to this corrected disclosure, not necessarily a complete replacement of earlier positions.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $1.16 · Expires 2032-03-13 | Direct | 466,054 |
Reported balance
After 2022-03-14 transaction · row 1
Amendment: may correct only part of an earlier disclosure.
1 source rowRow 1 · 2022-03-14 · Grant · Acquired 466,054 · Balance 466,054 F1: The options shall vest in four approximately equal installments on each of the first four anniversaries of March 14, 2022, in each case subject to the Reporting Person continuing in service through the applicable vesting date. |
Filing footnotes · ownership attribution and instrument terms
F1: The options shall vest in four approximately equal installments on each of the first four anniversaries of March 14, 2022, in each case subject to the Reporting Person continuing in service through the applicable vesting date.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| March 15, 2023 Filed Mar 17, 2023 01:19 UTC | Bioventus Inc. BVS · Entity 4996 | SaleClass A Common Stock | 9,811 | $1.39 | $13,624.54 |
DisclosureSEC source: 0000899243-23-008792 · doc4.xml · nonDerivative · entry 2 Reali Kenneth Michael · CIK 0001480801 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 30,085 F2 · kind: Reflects shares sold to cover taxes upon the vesting of the RSUs on March 14, 2023 pursuant to a standing 10b5-1 instruction. F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions ranging from $1.37 to $1.43, inclusive. Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote. Read SEC document |
| March 14, 2023 Filed Mar 17, 2023 01:19 UTC | Bioventus Inc. BVS · Entity 4996 | Exercise / conversionRestricted Stock Units · Derivative | 28,721 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-23-008792 · doc4.xml · derivative · entry 4 Reali Kenneth Michael · CIK 0001480801 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 86,161 Underlying: Class A Common Stock · 28,721 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit ("RSU") represents a contingent right to receive one share of Class A common stock. F4 · derivative.exercise_date: The original grant of 114,882 RSUs vest in four approximately equal annual installments beginning on March 14, 2023. F4 · derivative.expiration_date: The original grant of 114,882 RSUs vest in four approximately equal annual installments beginning on March 14, 2023. Read SEC document |
| March 14, 2023 Filed Mar 17, 2023 01:19 UTC | Bioventus Inc. BVS · Entity 4996 | Exercise / conversionClass A Common Stock | 28,721 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000899243-23-008792 · doc4.xml · nonDerivative · entry 1 Reali Kenneth Michael · CIK 0001480801 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 39,896 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit ("RSU") represents a contingent right to receive one share of Class A common stock. Read SEC document |
| March 14, 2022 Filed Mar 17, 2023 01:19 UTC | Bioventus Inc. BVS · Entity 4996 | GrantRestricted Stock Units · Derivative | 114,882 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-23-008792 · doc4.xml · derivative · entry 3 Reali Kenneth Michael · CIK 0001480801 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 114,882 Underlying: Class A Common Stock · 114,882 shares Expires not disclosed F1 · derivative.exercise_price: Each restricted stock unit ("RSU") represents a contingent right to receive one share of Class A common stock. F4 · derivative.exercise_date: The original grant of 114,882 RSUs vest in four approximately equal annual installments beginning on March 14, 2023. F4 · derivative.expiration_date: The original grant of 114,882 RSUs vest in four approximately equal annual installments beginning on March 14, 2023. Read SEC document |
| March 14, 2022 Filed Apr 21, 2023 21:19 UTC Amendment | Bioventus Inc. BVS · Entity 4996 | GrantStock Option (Right to Buy) · Derivative | 466,054 | $0.00 Strike: $1.16 | $0.00 |
DisclosureSEC source: 0001578563-23-000024 · primary_doc.xml · derivative · entry 1 Reali Kenneth Michael · CIK 0001480801 · Director · Fmr. CEO and Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 466,054 Underlying: Class A Common Stock · 466,054 shares Expires 2032-03-13 F1 · derivative.exercise_date: The options shall vest in four approximately equal installments on each of the first four anniversaries of March 14, 2022, in each case subject to the Reporting Person continuing in service through the applicable vesting date. Read SEC document |
| September 09, 2021 Filed Sep 10, 2021 13:22 UTC | Bioventus Inc. BVS · Entity 4996 | PurchaseClass A Common Stock | 1,800 | $14.81 | $26,658.00 |
DisclosureSEC source: 0000899243-21-035518 · doc4.xml · nonDerivative · entry 1 Reali Kenneth Michael · CIK 0001480801 · Director · CHIEF EXECUTIVE OFFICER 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 11,175 Read SEC document |
| April 01, 2021 Filed Apr 5, 2021 20:31 UTC | Bioventus Inc. BVS · Entity 4996 | GrantStock Options · Derivative | 30,000 | $0.00 Strike: $15.23 | $0.00 |
DisclosureSEC source: 0000899243-21-014831 · doc4.xml · derivative · entry 2 Reali Kenneth Michael · CIK 0001480801 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 30,000 Underlying: Class A Common Stock · 30,000 shares Expires 2031-03-31 F1 · derivative.exercise_date: The stock option vests in four equal annual installments beginning on April 1, 2022. Read SEC document |
| February 11, 2021 Filed Apr 5, 2021 20:31 UTC | Bioventus Inc. BVS · Entity 4996 | PurchaseCommon Stock | 9,375 | $13.00 | $121,875.00 |
DisclosureSEC source: 0000899243-21-014831 · doc4.xml · nonDerivative · entry 1 Reali Kenneth Michael · CIK 0001480801 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,375 Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.